Rigel Pharmaceuticals Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Rigel Pharmaceuticals Inc in the third quarter 2026?
Rigel Pharmaceuticals Inc achieved a return on average equity (ROE) of 73.94 % in its third quarter 2026, this is above RIGL's average return on equity of -87.09%.
Rigel Pharmaceuticals Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $415 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 11 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 56, from total ROE ranking in the second quarter 2026 at 62.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	278.46 %	419.23 %	2053.81 %	11806.33 %	-
Y / Y Net Income Change	-52.74 %	-71 %	-24.39 %	1769.22 %	124.62 %
Net Income (TTM) in Millions	307	322	364	367	113
Return On Equity (TTM)	73.94 %	96.49 %	147.03 %	240.83 %	204.7 %
RIGL's Total Ranking	# 56	# 62	# 20	# 22	#
Equity (TTM) in Millions	445	425	400	391	118
Seq. Equity Change	4.63 %	6.38 %	2.15 %	232.87 %	43.54 %
Seq. Net Income Change	-23.74 %	99.79 %	-96.77 %	860.81 %	-53.2 %

Back to RIGL Management Effectiveness >> RIGL's 5 Years Annual ROE >> Compare RIGL ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 12
Sector	# 25
Overall	# 56

Return On Equity Statistics
High	Average	Low
438.89 %	-87.09 %	-2419 %
(Jun 30 2025)		(Sep 30 2022)

RIGL Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	391	3	-29	-14	30
Y / Y Equity Change	11806.33 %	-	-	-	-10.73 %
Net Income in Millions	367	17	-25	-59	-18
Y / Y Net Income Change	1999.08 %	-	-	-	-
Return On Equity	93.75 %	531.78 %	-	-	-58.98 %

Back to RIGL Management Effectiveness >> RIGL's 5 Years Annual ROE >> Compare RIGL ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 93.75 %, despite net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RIGL's' Return on Equity at Yahoo Finance
RIGL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RIGL's Competitors
Subscribers only: Roe for Rigel Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Equity for RIGL's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Alnylam Pharmaceuticals Inc	159.72 %
Alector Inc	112.21 %
Medpace Holdings Inc	99.76 %
3m Company	93.07 %
Exelixis Inc	85.83 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %

Date modified: 2026-11-09T06:44:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.